NEW YORK, Aug. 20 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation (Nasdaq: GNBT). The full 64-page report can be found at http://www.crystalra.com.
Generex Biotechnology Corporation ("Generex" or "the Company") is a specialty pharmaceutical company that aims to research, develop, and commercialize drug delivery systems and technologies to treat autoimmune disorders, cancers, and infectious and metabolic diseases. Generex's RapidMist(TM) platform technology is a device and liquid formulation combination that can deliver medications to the bloodstream via the buccal mucosa at an improved absorption rate. This formulation is partially composed of absorption enhancers, called surfactants, which enable the oral delivery of a range of compounds, including macromolecules. While the device's appearance is similar to a pulmonary inhaler, the technology differs greatly. Traditional inhalers deliver medication into the lungs; RapidMist(TM) delivers larger-sized molecules into the buccal mucosa of the mouth, with no lung deposition.
The Company's lead product, Generex Oral-lyn(TM), is a buccal insulin spray that uses the RapidMist(TM) platform to treat Type 1 and Type 2 diabetes, which has demonstrated safety and efficacy in clinical trials. Generex Oral-lyn(TM) is currently approved in Ecuador and India. Generex has enrolled over 150 patients in a Phase III trial of Generex Oral-lyn(TM) at 39 clinical sites worldwide. The Company is also developing MetControl(TM) gum to avoid some of the adverse side effects associated with generic metformin tablets. This product candidate could have a shorter path to commercialization as metformin is already an established standard of care for Type 2 diabetes. Generex's wholly owned subsidiary, Antigen Express, Inc., develops prophylactic, immunotherapeutic, and diagnostic candidates through proprietary platform technologies that modulate the immune system to elicit specific responses. Antigen Express's most advanced compound is a breast cancer vaccine in Phase II trials with the U.S. Military Cancer Institute's Clinical Trials Group. In August 2008, Generex began enrolling patients in a Phase I breast and ovarian cancer trial using two immunotherapeutic vaccines designed to function in concert.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and Delray Beach. Crystal Research Associates has been compensated by the Company in cash of forty thousand U.S. dollars for its services in creating the base report, for updates, and for printing costs.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
|SOURCE Crystal Research Associates, LLC|
Copyright©2008 PR Newswire.
All rights reserved